Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 49

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 49
---
          |     | Stock Awards |     |          |     | Option Awards |     |        |     |          |     |          |
| Name                 |     | Grant    
 Date     |     |       Number 
           of 
       Shares |     |    Grant 
     Date 
     Fair 
 Value(1) |     | Exercise      
 Price         |     | Number 
 of     
 Shares |     | Grant    
 Date     
 Fair     
 Value(1) |     |    Total 
    Grant 
     Date 
     Fair 
 Value(1) |
| Stephen Pakola, M.D. |     | 8/1/2024 |     |       58,386 |     | $777,118 |     | —             |     | —      |     | $—       |     | $777,118 |
| Olivier Danos, Ph.D. |     | 8/1/2024 |     |       58,867 |     | $783,520 |     | —             |     | —      |     | $—       |     | $783,520 |
| Patrick J. Christmas |     | 8/1/2024 |     |       56,446 |     | $751,296 |     | —             |     | —      |     | $—       |     | $751,296 |

(1) Amounts represent the aggregate grant date fair value of options and/or RSUs, as applicable, granted during 2024 calculated in accordance with FASB ASC Topic 718. See Note 11, “Stock-based Compensation,” to the financial statements included in our Annual Report for a discussion of the assumptions we made in determining the grant date fair value of our equity awards. Timing of Equity Grants The timing of annual equity compensation award grants has been generally consistent. Grants are typically made at the regularly scheduled meetings of our Compensation Committee in January, to provide grants to Company executives, and as of the date of our annual meeting of stockholders, to provide grants to the Board. We do not have any program, plan or obligation that requires us to grant equity awards on specified dates, although when we make annual equity grants, the Compensation Committee and the Board review all elements of compensation at the same points in the year. We do not have any program, plan or practice to time grant dates of equity compensation awards to our executive officers in coordination with the release of material nonpublic information. The Board, with respect to our CEO, and the Compensation